Supporting innovation, excellence and the highest ethical standards focused on taking stem cell discoveries from the lab to the patient. (RT≠endorsement)
Our director, Dr. Sanaz Memarzadeh, will be giving a UCLA Health Jonsson Comprehensive Cancer Center Research Seminar discussing the current prospects in Gynecologic Oncology research as the field advances and expands to meet the clinical need.
Please see the flyer for details.
At UCLA, Dr. David Nathanson is designing new therapies that tackle glioblastoma’s unique tumor biology, aiming to overcome long-standing treatment challenges. https://t.co/VgAplSpWY8
By day, Dr. Anthony Aldave advances gene therapy for inherited corneal disorders. After hours, he’s spinning EDM.
Learn about the @UCLASteinEye surgeon-scientist’s path to ophthalmology, global training work and mission to restore sight: https://t.co/jLYutPQaX3
Congratulations to Dr. Aparna Bhaduri @BhaduriLab for receiving the 2026 Pershing Square Sohn Cancer Prize, a national award recognizing innovative early-career scientists pursuing bold approaches to cancer research! 🎉
🔗 https://t.co/G2kFdCyPR7
#ResearchPowersProgress
Meet Dr. Anthony Aldave, a corneal surgeon @UCLASteinEye & #GeneTherapy pioneer working to restore sight for people with inherited corneal disorders.
Learn about his path to ophthalmology, global surgical training work and after-hours life as a DJ: https://t.co/jLYutPQaX3
Don't miss Xiaowei Zhuang, Ph.D. of @Harvard University present, "Spatially Resolved Single-Cell Genomics & Functional Genomics," on Friday, May 8 at 12PM PT via Zoom: https://t.co/rIcpgGMD3V
@UCLAHealth
Aging biology is moving fast. New work from @dgsomucla from @ACovarrubiasPhD highlights how “zombie” immune cells (senescent macrophages) in the liver build up with age and drive chronic inflammation. A powerful example of how training, discovery & collaboration are advancing our understanding of aging—and pointing toward new therapies.
https://t.co/uI4ItGeRZC
Hair loss treatments haven’t meaningfully changed in decades. Pelage was built to change that.
We're advancing PP405, a topical therapy designed to reactivate dormant hair follicle stem cells to restore hair growth, with plans to initiate late-stage trials later this year. Read our full story below. https://t.co/LhTmPAl1t0
For the first time, UCLA scientists @LTULab have mapped how Down syndrome reshapes the human brain before birth — uncovering surprising shifts in neuron development that may explain differences in brain size and cognition.
Read more ➡️https://t.co/wTZCXfavhk #BrainDevelopment
A clinical trial for sickle cell disease that UCLA's @Kohn_Lab led over nearly a decade yields hard-won insights — and a roadmap for better clinical trial design for blood diseases.
Read more ➡️ https://t.co/gfsP5dbSb6
#ResearchPowersProgress#SickleCellDisease#GeneTherapy
In collaboration with Dr. Jasmine Zhou and an incredible team of UCLA scientists, our director has published in the Proceedings of the National Academy of Sciences a new low-cost blood test to detect and monitor many diseases including ovarian cancer.
https://t.co/90o5EP5p3k
About 1 in 3 Angelenos has fatty liver disease. @UCLA scientists may have just found a new way to treat it by targeting dysfunctional immune cells dubbed "zombie cells." 🧟🧫
#ResearchPowersProgress@ACovarrubiasPhD
https://t.co/gkbFAJQ3zX
Online now!✨RESEARCH: Salladay-Perez and colleagues interrogate whether macrophages can really undergo senescence, and characterize a p21+Trem2+ senescent macrophage population functionally implicated in inflammaging and liver disease @ACovarrubiasPhD https://t.co/19DfqeYY3g
ICYMI: FDA approval of a new gene therapy marks a major advance in treating a rare and life-threatening immune disorder in children. https://t.co/GNVkoQ2L6n
The FDA has approved a gene therapy developed at UCLA for a rare immune disorder, with clinical trial patients showing restored immune function. https://t.co/GJVvd261lA
All 3 Langenhop kids were born with a rare, often-fatal immune disorder called LAD-I. After joining a UCLA #GeneTherapy trial, they're now "normal, happy kids" with functional immune systems.
Their trial participation helped make last week’s FDA accelerated approval possible.
💙
In collaboration with @RocketPharma , we celebrate the first FDA-approved gene therapy supported by @CIRMnews and CA taxpayer funding. #raredisease matters.
The FDA approved a gene therapy for severe leukocyte adhesion deficiency type 1 (LAD-1), an ultra-rare disease that leaves children vulnerable to life-threatening infections. https://t.co/iEWI6fFpKb
How does the FDA-approved LAD-I gene therapy work?
Doctors take the patient's OWN stem cells, add a healthy copy of the mutated gene, and return them.
No donor needed. No transplant rejection risk. All 9 trial patients: restored immune systems.
🔗 https://t.co/gDPLIrKPwX